The levels of circulating CD31+/CD41a− endothelial microparticles (EMPs) and platelet microparticles (PMPs) were higher in patients with diabetes who received intra-arterial (IA) iohexol than in those who received iodixanol or patients without diabetes who received iohexol, whereas CD62E+ EMPs decreased significantly in patients receiving iodixanol. Here, PECAM1 is linked to diabetes mellitus.